Inovio Pharmaceuticals (INO) surged almost 10% after the company said that preclinical study data results of its potential vaccine candidate showed “robust” neutralizing antibody and T cell immune responses against coronavirus.Shares rose 9.5% to $15.94 in midday U.S. trading. The value of the stock has this year gone up five-fold with investors excited about Inovio’s potential Covid-19 vaccine INO-4800. The vaccine drug candidate targets the major antigen Spike protein of SARS-CoV-2 virus, which causes Covid-19 disease."These positive preclinical results from our Covid-19 DNA vaccine not only highlight the potency of our DNA medicines platform, but also build on our previously reported positive Phase 1/2a data from our vaccine against the coronavirus that causes MERS, which demonstrated near-100% seroconversion and neutralization from a similarly designed vaccine INO-4700,” said Kate Broderick, Inovio's Senior VP of R&D. “The potent neutralizing antibody and T cell immune responses generated in multiple animal models are supportive of...
Fifty early bitcoins have been moved from a wallet that's been dormant since 2009.The post Someone just moved a block of bitcoins first mined in February 2009 appeared first on The Block....
The cruise industry has faced the brunt of the health crisis as major outbreaks in ships were blamed for spreading the disease, resulting in government-mandated "no-sail" orders and trip cancellations. Royal Caribbean, which warned of a second-quarter loss in the face of a mounting debt, said it would have to pay between $590 million and $610 million in interest for the rest of the year on borrowings to the tune of more than $5 billion. Rivals Carnival Corp and Norwegian Cruise Line have also signaled a similar return in demand....